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SurvivalAbstract Background and aims: To study the clinico-pathological features, treatments and out-
comes of gastric carcinoma (GC) in the elderly (P65 years) and the non-elderly Egyptian patients.
Methods: This retrospective cohort study included 168 patients with histologically conﬁrmed GC
treated at Tanta Cancer Center between 2003 and 2007.
Results: Compared to the non-elderly, elderly patients had signiﬁcantly higher proportion of
tumors involving the cardia (p= 0.034) and of adenocarcinoma NOS histology (p= 0.032). Treat-
ments were largely comparable in the two groups. Response to palliative chemotherapy was
achieved in 44.4% of the elderly and 25.5% of the non-elderly patients (p= 0.417). The median
overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 6, 17
and 3 months, respectively. The median OS was 4 months in the elderly compared to 9 months in
the non-elderly (p= 0.005). The median DFS was 4 months in the elderly compared to 20 months
in the non-elderly (p= 0.004). The median PFS was 2 months in the elderly compared to 3 months
in the non-elderly (p= 0.685). In multivariate analysis, poor performance status was an indepen-
dent predictor of poor OS, DFS and PFS. Non-curative or no surgery and lack of chemotherapy
use were independent predictors of poor OS. Age was an independent predictor of poor DFS.
Conclusions: Compared to the non-elderly, GC in the elderly has similar clinico-pathological char-
acteristics and exhibits comparable outcomes with the same treatment options. Treatments should
be tailored to each patient.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.
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The peak age for gastric cancer (GC) is 60–80 years [1]. GC in
the elderly represents a distinct entity with speciﬁc clinical and
pathological characteristics and the majority of affected
patients belong to this age group [2]. Worldwide, GC is the
5th most common malignancy in both sexes representing
6.8% of their total with an estimated 950,000 cases in 2012.
It is the 3rd leading cause of cancer death representing 8.8%
of the total cancer mortality with an estimated 725,000 deaths
in 2012. Incidence rates are about twice as high in men as in
women and mortality rates are high in both sexes [3]. The best
established risk factors are Helicobacter pylori infection, male
sex, a family history of GC, and smoking. Dietary risk factors
are related to diet type and food preservation, such as high
intake of salt-preserved foods and dietary nitrite or low intake
of fruit and vegetables [4]. More than 70% of GCs occur in
developing countries particularly in Eastern Asia [3].
In Egypt, GC is the 12th most common cancer in both sexes
representing 1.6% of the total cancers [3,5]. It is the 12th lead-
ing cause of cancer death representing 2.2% of the total cancer
mortality [3]. This is shown in many Egyptian population-
based cancer registries [6]. At the Egyptian National Cancer
Institute (ENCI), GC is the 14th most common cancer repre-
senting 1.8% of cases in both sexes [7]. The median age of
GC in the Egyptians is 56 years [5]. The incidence rises with
age and 55% of cases occur between 50 and 70 years of age [8].
When treating patients with GCs, factors related to the
patient (comorbidities, performance status [PS], and age), to
the tumor (location, histology, and stage) and to the treatment
(surgical experience, adjuvant treatment risk-beneﬁt ratio)
should be considered [9]. Whenever possible, complete resec-
tion of the tumor is the standard treatment. Extent of resection
(partial or total gastrectomy) is based on tumor location,
stage, histology, and surgical margins. The extent of regional
lymphadenectomy required has been a matter of considerable
debate. Randomized controlled trials show that extended (D2)
lymphadenectomy is safe and able to cure 20% of patients with
N2-disease compared with 0% treated with limited D1 dissec-
tion [9]. Postoperative decisions about adjuvant chemotherapy
and radiotherapy can reduce recurrence and mortality and the
decision is based on pathologic staging, the extent of surgery
(D0/D1 vs. D2/D3) and the risk–beneﬁt ratio [9].
Adjuvant therapies differ in various regions of the world
[10]. In the USA, the Intergroup 0116 trial established the
use of postoperative chemo-radiotherapy using ﬂuorouracil/
leucovorin as a standard for patients who had upfront surgery
[11]. In Europe, the MAGIC trial demonstrated the beneﬁts of
perioperative ECF chemotherapy [12]. In Asia, the ACTS-GC
[13] and CLASSIC trials [14] established postoperative chemo-
therapy using S-1 or capecitabine/oxaliplatin as the standard
of care after primary surgery that included D2 dissection. In
metastatic GC, chemotherapy is the mainstay treatment with
capecitabine and oxaliplatin being as effective as ﬂuorouracil
and cisplatin [15]. Added to chemotherapy in HER-2 positive
metastatic GC, trastuzumab signiﬁcantly prolonged survival
[16]. Studies showed that elderly patients with non-metastatic
GCs, curative gastrectomy with lymph node dissection [17]
and adjuvant ﬂuoropyrimidine-based chemotherapy [18] are
reasonably tolerated and produce beneﬁts comparable to those
in the non-elderly.It is not clearly known whether treatments of GCs in elderly
Egyptian patients (aged 65 years or more) are as tolerable and
effective as that in the non-elderly patients. The aim of the
study was to evaluate safety and efﬁcacy of GC therapy in
elderly Egyptian patients and compare this to the non-elderly.
Methods
This is a retrospective study. Patients with histologically
proven GC presenting to Tanta Cancer Center (TCC) between
the years 2003 and 2007 were included. Data on age, sex,
clinical presentation, comorbidities, tumor location, histology,
grade and stage, treatment modalities, response, tolerance,
relapse/progression, dates of diagnosis, surgery and relapse/
progression, and last follow up were extracted from the
medical records. The study was approved by the IRB of the
Egyptian National Cancer Institute. Overall survival (OS) is
deﬁned as the time between diagnosis and death or last
follow-up. Disease-free survival (DFS) is the time between
curative surgery and recurrence or death. Progression-free sur-
vival (PFS) is the time between the start of palliative therapy
and progression or death.
Statistical analysis
All analyses were done using SPSS software program version
21 (Chicago, USA). The Chi squared or Fisher’s exact test was
used to compare nominal or categorical variables. Medians
were compared using the Mann–Whitney’s U test. Survival
was calculated using the Kaplan Meyer method and groups
were compared using the log-rank test. A probability (p) of less
than 0.05 (two sided) was considered statistically signiﬁcant.
Stepwise Cox-regression Hazard Model was used to assess
the independent impact on survival of parameters with a
p-value of 60.0.05 in the log-rank test.Results
Patients’ characteristics
Between 2003 and 2007, 168 cases of GCs presented to TCC.
All were histologically conﬁrmed and subtyped. The median
age was 54 years (range 21–82 years) with male predominance
(Table 1). All cases had symptoms related to their disease.
Abdominal pain was the commonest presentation followed
by vomiting, hematemesis/melena, dysphagia and abdominal
mass/distension. Comorbidities were infrequently encountered
with hypertension and diabetes mellitus being the commonest.
Most patients had performance status (PS) of 1 or 2. The car-
dia, pylorus and overlapping sites were the most common
tumor locations within the stomach. Adenocarcinoma not
otherwise speciﬁed (NOS) was the commonest histological
subtype (Table 2). Most patients presented at an advanced
stage i.e. TNM stage III or IV and peritoneal and liver metas-
tases were the commonest sites of metastases.
Elderly constituted 22.6% of the cases. Compared to the
non-elderly, elderly patients had signiﬁcantly higher propor-
tion of tumors involving the Cardia (p= 0.034), of adenocar-
cinoma NOS histology (p= 0.032) and of low-grade histology
only in the non-metastatic setting (p= 0.041). Otherwise,
Table 1 Clinical characteristics of 168 patients with gastric carcinoma according to age at diagnosis.
Total
N (%)
<65 years
N (%)
P65 years
N (%)
P
168 (100.0) 130 (77.4) 38 (22.6)
Age
Mean ± SD 54.1 ± 12.3 49.3 ± 9.6 70.2 ± 4.6 –
Sex
Male 95 (56.5) 72 (55.4) 23 (60.5)
Female 73 (43.5) 58 (44.6) 15 (39.5) 0.574
Clinical presentation
Abdominal pains 75 (44.6) 60 (46.2) 15 (39.5)
Vomiting 63 (37.5) 53 (40.8) 10 (26.3)
Hematemesis/melena 26 (15.5) 14 (10.8) 12 (31.6)
Dysphagia 20 (11.9) 14 (10.8) 6 (15.8)
Mass/distension 15 (8.9) 14 (10.8) 1 (2.6)
Fatigue/weight loss 11 (6.5) 9 (6.9) 2 (5.3)
Intestinal obstruction 5 (3.0) 4 (3.1) 1 (2.6) –
Comorbidities
Yes 24 (14.3) 18 (13.8) 6 (15.8)
No 144 (85.7) 112 (86.2) 32 (84.2) 0.794
Performance Status 166 128 38
1–2 142 (84.5) 110 (85.9) 32 (84.2)
3–4 24 (15.5) 18 (14.1) 6 (15.8) 0.795
Site
Cardia 32 (19.0) 20 (15.4) 12 (31.6)
Fundus, body, curves 37 (22.0) 33 (25.4) 4 (10.5)
Antrum and pylorus 45 (26.8) 37 (28.5) 8 (21.1)
Overlap/unspeciﬁed 54 (32.1) 40 (30.8) 14 (36.8) 0.047
SD: standard deviation.
Table 2 Pathological characteristics of 168 patients with gastric carcinoma according to age at diagnosis.
Characteristic Total
N (%)
Age <65 years
N (%)
Age P65 years
N (%)
P
Histologic subtype
Adenocarcinoma (AC) NOS 80 (47.6) 56 (43.1) 24 (63.2)
Signet ring AC 52 (31.0) 44 (33.8) 8 (21.1)
Mucinous AC 7 (4.2) 6 (4.6) 1 (2.6)
Anaplastic carcinoma 23 (13.7) 19 (14.6) 4 (10.5)
Other carcinomas 6 (3.6) 5 (3.8) 1 (2.6) –
Histology grouping 162 125 37
Adenocarcinoma (AC) NOS 80 (49.4) 56 (44.8) 24 (64.9)
Signet-ring, mucinous, anaplastic 82 (50.6) 69 (55.2) 13 (35.1) 0.032
Grade 167 129 38
G1–2 70 (41.9) 50 (38.8) 20 (52.6)
G3–4 97 (58.1) 79 (61.2) 18 (47.4) 0.128
TNM stage 162 126 36
I 13 (8.0) 11 (8.7) 2 (5.6)
II 35 (21.6) 27 (21.4) 8 (22.2)
III 56 (34.6) 42 (33.3) 14 (38.9)
IV 58 (35.8) 46 (36.5) 12 (33.3) 0.876
Site of mets 58 46 12
Omental/peritoneal 36 (62.1) 31 (67.4) 5 (41.7)
Liver 30 (51.7) 24 (52.2) 6 (50)
PALN LN 14 (24.1) 10 (21.7) 4 (33.3)
Lung/mediastinal LN/eﬀusion 7 (12.1) 4 (8.7) 3 (25.0)
Bone/bone marrow 4 (6.9) 4 (8.7) 0 (0)
Skin 1 (1.7) 1 (2.2) 0 (0)
Supraclav LN 3 (5.2) 2 (4.3) 1 (8.3)
Pelvic LN 2 (3.4) 1 (2.2) 1 (8.3) –
NOS: not otherwise speciﬁed, LN: lymph node metastasis.
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characteristics between the two groups (Tables 1 and 2).
Treatments
Surgery and chemotherapy were used in 71.4% and 54.8%
patients, respectively, while chemo-radiotherapy was used in
7.1% (Table 3). Surgery was of curative intent in 44.8% of
cases. Total gastrectomy was the commonest procedure and
R0 resection was achieved in the majority of cases with no sig-
niﬁcant differences between elderly and non-elderly patients.
Chemotherapy was used in 55.8% of patients with almost
equal distribution between the adjuvant and palliative settings
for a median of 3 cycles (range, 1–8). Cisplatin/Fluorouracil
and Fluorouracil/calcium leucovorin were the two regimens
used. In the palliative setting, the overall response rate was
30.2%. There were no signiﬁcant differences regarding
chemotherapy use, intent, regimens, cycle numbers or responseTable 3 Treatments used in 168 gastric carcinoma patients accordi
All years
n (%)
Treatments 168
None 5 (3.0)
Surgery 120 (71.4)
Chemotherapy 92 (54.8)
Concomitant CRT (FU) 12 (7.1)
Surgery 163
No 43 (26.4)
Exploration/palliative 47 (28.8)
Curative 73 (44.8)
Curative surgical procedure 73
Total gastrectomy 63 (86.3)
Partial gastrectomy 10 (13.7)
Surgical residual after curative 73
R0 63 (86.3)
R1 10 (13.7)
90-day postoperative mortality 73
Yes 5 (6.8)
No 69 (93.2)
Chemotherapy 165
Yes 92 (55.8)
No 73 (44.2)
Chemotherapy mode 92
Adjuvant 47 (51.1)
Palliative 45 (48.9)
Chemotherapy regimen 92
FL 53 (57.6)
CF 39 (42.6)
Chemotherapy cycles 92
Median (range) 3 (1–8)
Response to palliative chemotherapy 45
CR 2 (4.4)
PR 11 (24.4)
SD 11 (24.4)
PD 19 (42.8)
Unknown 2 (4.4)
Response group 43
Response 13 (30.2)
No response 30 (69.8)
CRT: concomitant chemo-radiotherapy, FU: ﬂuorouracil, CF: cisplat
response, PR: partial response, SD, stable disease, PD: progressive diseabetween the elderly and the non-elderly patients (Table 3).
Chemotherapy was tolerated comparably in both groups.
Adjuvant chemo-radiotherapy was used occasionally and
almost exclusively in the non-elderly patients. Radiotherapy
or concomitant chemo-radiotherapy was given adjuvant to
surgery in 4 and 8 non-elderly patients, respectively with posi-
tive surgical margin and nodal involvement.
Overall survival
After a median follow up of 29 months (95% conﬁdence inter-
val [CI], 9.7–48.3), 111 patients were dead. For the whole
group, the median OS was 6 months (95% CI, 3.3–8.7). The
median OS was 4 months in the elderly patients compared to
9 months in the non-elderly (p= 0.005) (Fig. 1). Compared
to the other counterparts (Table 4), OS was signiﬁcantly lower
in patients who had advanced stage (p= 0.001), poor PS
(p< 0.001), did not undergo curative surgery (p< 0.001) orng to age at diagnosis.
Age <65 years
n (%)
Age P65 years
n (%)
P
130 38 –
3 (2.3) 2 (5.3)
92 (70.8) 28 (73.7)
74 (56.9) 18 (47.4)
11 (8.5) 1 (2.6) –
127 36 0.316
35 (27.6) 8 (22.2)
35 (27.6) 12 (33.3)
57 (44.9) 16 (44.4) 0.730
57 16
49 (86.0) 14 (87.5)
8 (14.0) 2 (12.5) 0.100
57 16
49 (86.0) 14 (87.5)
8 (14.0) 2 (12.5) 1.000
57 16
4 (7.0) 1 (6.3)
53 (93.0) 16 (93.7) 0.699
128 37
74 (57.8) 18 (48.6)
54 (42.2) 19 (51.4) 0.249
74 18
39 (52.7) 8 (44.4)
35 (47.3) 10 (55.6) 0.530
74 18
43 (58.0) 10 (55.5)
31 (42.0) 8 (44.5) 1.000
74 18
3 (1–8) 2 (2–6) 0.249
35 10
2 (5.7) –
7 (20) 4 (40)
10 (28.9) 1 (10)
15 (43.5) 4 (40)
1 (2.9) 1 (10) –
34 9
9 (26.5) 4 (44.4)
25 (73.4) 5 (55.6) 0.417
in/ﬂuorouracil, FL: ﬂuorouracil/calcium leucovorin, CR: complete
se.
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received chemotherapy had superior survival to those who
did not receive such therapy (p= 0.024).
In patients who underwent curative surgery, the median OS
was 35 months with adjuvant therapy signiﬁcantly compared
to 11 months without adjuvant therapy (p= 0.02). This was
also demonstrated in the non-elderly (36 months vs.
11 months; p= 0.011) but not in the elderly (6 months vs.
5 months; p= 0.459). With adjuvant therapy, the median OS
was 36 months in the non-elderly compared to 6 months in
the elderly (p< 0.001).
In patients who did not undergo curative surgery, palliative
chemotherapy produced a median OS of 6 months compared
to 2 months in patients who did not receive chemotherapy at
all (p= 0.144) with no signiﬁcant difference between the
elderly and non-elderly (p= 0.963).
In the multivariate analysis, poor performance status, non-
curative or no surgery at all, and not receiving chemotherapy
were independent predictors for poor survival. The hazard of
death in patients with PS 3–4 was 2.69 times that of patients
with PS 1–2 (p< 0.001). The hazard of death in patients
who had no curative surgery or no surgery at all was 2.55 times
that of patients who had curative surgery (p< 0.001). The
hazard of death in patients who did not receive chemotherapyTable 4 Overall survival (OS) in 168 patients with gastric carcinom
Group Number 2
All 168 2
Age
<65 years 130 2
P65 years 38 8
Sex
Male 95 2
Female 73 1
Site
Cardia 32 1
Fundus, body, curves 37 2
Antrum, pylorus 45 2
Overlapping, unspeciﬁed 54 1
Histology
Adenocarcinoma NOS 80 1
Other 82 1
Grade
Low (1–2) 70 2
High (3–4) 97 1
TNM stage group
I–III 104 3
IV 58 4
Performance status
Good (1,2) 142 2
Poor (3,4) 42 0
Surgery
No 43 6
Non-curative 47 5
Curative 73 4
Adjuvant treatment
Yes 47 5
No 26 2
Chemotherapy
Yes 92 2
No 46 1
SE: standard error, 2YOSR: 2-year OS rates, 5YOSR: 5-year OS rates, Awas 1.71 times that of patients who received chemotherapy
(p= 0.007). Age was not an independent predictor of poor
survival (Table 7).
Disease-free survival
For the 73 patients who underwent curative surgery, the
median DFS was 17 months (95% CI, 5.4–28.6; Table 4).
The median DFS was 4 months in the elderly patients com-
pared to 20 months in the non-elderly (p= 0.004) (Fig. 2).
The median DFS in patients with PS 0–2 was 17 months com-
pared to 0.3 months in patients with PS 3 (p< 0.001). The
median DFS was 23 months with adjuvant therapy compared
to 5 months without adjuvant therapy (p= 0.026; Table 5).
This trend was also shown in the non-elderly (27 months vs.
9 months; p= 0.006) but not in the elderly (3 months vs.
4 months; p= 0.327). Adjuvant therapy was associated with
a median DFS of 27 months in the non-elderly compared to
3 months in the elderly (p< 0.001).
In the multivariate analysis, elderly age and poor PS were
predictors of poor DFS. The hazard of death in patients
P65 years was 2.61 times that of patients <65 years
(p= 0.015). The hazard of death in patients with PS 3–4 was
4.49 times that of patients with PS 1–2 (p= 0.004; Table 7).a.
YOSR (SE) 5YOSR (SE) P
0 (3.8) –
3.1 (4.6) 14.2 (4.2)
.4 (5.6) 0 (0) 0.005
1.7 (5.5) 13.8 (5.1)
8.3 (5.3) 8.0 (4.2) 0.624
8.5 (9.2) 0 (0)
0.6 (8.1) 15.4 (7.5)
2.8 (7.7) 15.2 (6.7)
7.5 (6.2) 7.0 (5.8) 0.657
9.1 (5.5) 3.2 (3.0)
9.6 (5.4) 14.7 (5.0) 0.841
1.4 (6.1) 9.2 (5.5)
8.5 (4.9) 11.1 (4.1) 0.234
0.2 (5.7) 17.9 (5.4)
.7 (3.2) 2.3 (2.3) 0.001
3.3 (4.4) 12.5 (3.8)
(0) 0 (0) <0.001
.2 (4.2) 3.1 (3.0)
.7 (3.9) 0 (0)
3.4 (7.4) 28.0 (7.9) <0.001
5.0 (8.8) 41.2 (10.7)
2.3 (11.0) 7.4 (7.1) 0.024
5.1 (5.5) 16.3 (5.5)
1.1 (5.1) 2.8 (2.7) 0.005
C NOS: adenocarcinoma not otherwise speciﬁed.
Table 5 Disease-free survival (DFS) in 73 patients with gastric carcinoma who had curative surgery.
Group Number 2YDFSR (SE) 5YDFSR (SE) P
All 73 39.0 (7.5) 24.3 (7.5) –
<65 years 57 44.5 (8.5) 30.5 (8.9)
P65 years 16 11.9 (11.1) 0 (0) 0.004
Sex
Male 48 42.5 (9.7) 26.6 (9.5)
Female 25 32.0 (11.9) 21.3 (11.8) 0.594
Site
Cardia 21 28.7 (13.7) 0 (0)
Fundus, body, curves 17 36.6 (14.2) 36.6 (14.2)
Antrum, pylorus 17 57.2 (15.6) 34.2 (15.6)
Overlapping, unspeciﬁed 18 31.9 (13.3) 31.9 (13.3) 0.420
Histology
Adenocarcinoma NOS 38 37.1 (10.6) 16.5 (9.5)
Other 32 45.7 (10.6) 36.6 (11.8) 0.861
Grade
Low (1–2) 33 46.3 (12.2) 37.0 (12.8)
High (3–4) 40 33.3 (9.2) 16.6 (8.2) 0.075
TNM stage group
I–II 33 39.4 (10.9) 19.7 (11.4)
III 37 42.0 (10.4) 30.0 (10.3) 0.619
Performance status
Good (1,2) 1–2: 65 42.5 (8.0) 26.5 (8.1)
Poor (3,4) 3: 6 0 (0) 0 (0) <0.001
Surgery
Total gastrectomy 59 39.2 (8.2) 22.9 (7.9)
Partial gastrectomy 14 27.0 (20.8) 27.0 (20.8) 0.552
Adjuvant treatment
Yes 47 45.2 (9.6) 33.0 (10.2)
No 26 28.3 (11.2) 9.4 (8.6) 0.026
SE: standard error, 2YDFSR: 2-year DFS rates, 5YDFSR: 5-year DFS rates, NOS: not otherwise speciﬁed, CTX: chemotherapy.
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For the 95 patients who did not undergo curative surgery, the
median PFS was 3 months (95% CI, 2.2–3.8; Table 6). The
median PFS was 2 months in the elderly patients compared
to 3 months in the non-elderly (p= 0.685) (Fig. 3). The
median PFS of patients with PS 0–2 was 3 months compared
to one month in patients with PS 3–4 (p= 0.002). For the sub-
set of patients who received palliative chemotherapy (n= 45),
the median PFS was 3 months in the elderly compared to
9 months in the younger patients (p= 0.890) and the median
OS was 5 months vs. 7 months respectively (p= 0.963).Discussion
Most GCs affect the elderly patients [2]. Life expectancy of the
Egyptians is 70–75 years being 5–6 years lower than the Amer-
ican [19]. The growth of elderly people in developing countries,
including Egypt, is projected to be faster than any other
segment of the population and at a rate higher than that of
developed countries [19]. Thus, GCs in the elderly will be an
emerging health problem.
The age at which a person is called elderly is somewhat
arbitrary. It is usually set as the age at which one can begin
to receive pension beneﬁts. Thus, the age of 60–65 years is
often used. The chronological age of 65 years is used by many
developed countries as an acceptable cut-off [20]. In Egypt, the
general retirement age is 60 years but this is proposed toincrease to 65 years starting from the year 2012 [21]. The def-
inition of elderly in clinical trials is more variable and is again
arbitrary [22]. In the current study, we adopted the age of
65 years as a cut-off being 5 years after the current retirement
age and also as a modest ﬁgure to allow comparisons with
other reports and to serve as a baseline for future comparisons.
Our GC cohort is largely similar to an older smaller
(n= 55) cohort treated at the ENCI between 1970 and 1977
[23]. Both cohorts were comparable regarding age at diagnosis,
male predominance, clinical presentations, predominant his-
tology and predominance of proximal tumors and pattern of
metastases. However, surgery was more frequent and chemo-
therapy was not reported in the older series. This reﬂects the
pattern of care during that time where surgery was the prevail-
ing treatment option and chemotherapy was not as developed
and as effective as it is nowadays. Our study provides more
thorough and updated analyses particularly relating to treat-
ments and their outcomes.
GC in the elderly has peculiar clinico-pathological charac-
teristics [2,17,24]. Male predominance is more pronounced in
the elderly [2]. This is conﬁrmed in the current study where
the M:F ratio was 1.53:1 in the elderly compared to 1.24:1 in
the non-elderly. This may reﬂect a more frequent and
prolonged exposure of male elderly patients to environmental
carcinogens [2].
Lower or distal third tumors were reported to be more com-
mon in the elderly (42–63%) than in the non-elderly (31–44%)
[2,25]. This may be related to differential impact of risk factors
particularly H. pylori in distal tumors and smoking in the
Table 6 Progression-free survival (PFS) in 95 patients with gastric carcinoma.
Group Number 6MPFS (SE) 12MPFS (SE) P
All 95 33.4 (5.4) 24.7 (5.5) –
Age
<65 years 73 36.4 (6.2) 26.8 (5.8)
P65 years 22 24.5 (10.4) 18.4 (9.4) 0.685
Sex
Male 47 24.1 (7.1) 18.0 (6.5)
Female 48 41.9 (7.7) 30.7 (7.4) 0.412
Site
Cardia 11 10.6 (10.0) 10.6 (10.0)
Fundus, body, curves 20 42.9 (12.8) 21.5 (10.9)
Antrum, pylorus 28 29.6 (9.8) 24.7 (9.3)
Overlapping, unspeciﬁed 36 39.1 (8.7) 31.1 (8.9) 0.169
Histology
Adenocarcinoma NOS 42 32.9 (7.7) 20.9 (6.8)
Other 50 35.0 (7.6) 29.1 (7.3) 0.969
Grade
Low (1–2) 35 42.2 (8.5) 29.2 (8.0)
High (3–4) 54 26.9 (6.8) 21.5 (6.4) 0.408
TNM stage group
II–III 37 35.5 (9.3) 26.6 (8.8)
IV 58 32.7 (6.8) 23.3 (6.3) 0.713
Performance status
Good (1,2) 77 40.0 (6.2) 29.1 (5.9)
Poor (3,4) 18 6.9 (6.6) 6.9 (6.6) 0.002
Surgery
No 43 39.4 (8.0) 24.3 (7.3)
Non-curative 47 28.8 (7.3) 25.9 (7.1) 0.293
Chemotherapy
Yes 45 42.0 (7.8) 25.2 (7.1)
No 47 25.5 (7.4) 22.3 (7.1) 0.549
SE: standard error, 6MPFSR: 6-month PFS rate, 12MPFSR: 12-month PFS rate, AC NOS: adenocarcinoma not otherwise speciﬁed.
Table 7 Multivariate analysis of factors affecting OS and DFS.
Variables in equation OS (n= 147) DFS (n= 71)
HR (CI) P HR (CI) P
Performance status (1 and 2 vs. 3 and 4) 2.69 (1.61–4.50) <0.001 4.49 (1.61–12.49) 0.004
Curative surgery (No vs. yes) 2.55 (1.66–3.91) <0.001 – –
Chemotherapy (No vs. yes) 1.71 (1.16–2.51) 0.007 – –
Age (P65 years vs.<65 years) – – 2.61 (1.20–5.69) 0.015
OS: overall survival, DFS: disease-free survival, HR= hazard ratio, CI: 95% conﬁdence interval.
Gastric Carcinoma in Elderly Egyptians 133proximal ones [26,27]. This is not shown in the current study
where distal third tumors were lower in the elderly patients
(30.8%) than in the non-elderly (40%) while the cardia was
higher. Similar to our ﬁndings, Hamzaki et al. reported pre-
dominance of proximal tumors in the elderly [28]. Difference
in deﬁnition of the elderly in trials (65+ vs. 70+ s. 75+
years), different patient populations with different risk factors
and difference in sample size might explain for the difference.
Moreover, almost 30% of tumor locations in the current study
were either unspeciﬁed (NOS) or overlapping.
Gastric carcinomas in the elderly may principally develop as
well-differentiated lesions which may later progress to poorly-
differentiated carcinomas. In contrast, GCs in the younger
age groups mostly emerge as poorly-differentiated tumors from
a very early phase [2]. Several studies have indicated that GCs
in elderly patients, irrespectively of tumor stage, are mainly welldifferentiated [2]. This is conﬁrmed in the current study where
52.6% of elderly had G1–2 tumors compared to 38.8% in the
non-elderly. The difference was most marked in the non-meta-
static setting (58% vs. 35%; p= 0.041).
Early studies had indicated that gastric cancer in elderly
patients exhibits less metastasizing activity and that its pattern
of metastases and recurrence is conﬁned to the area around the
primary focus in the upper abdomen including the liver
[2,25,29]. Later, Holmes and Hearne did not ﬁnd a signiﬁcant
positive correlation between age and advanced clinical stage in
gastric cancer [29]. Similarly, we did not ﬁnd signiﬁcant corre-
lation between age and stage. The early reports did not take
the histological type into consideration nor the pathological
stage of gastric cancer [2].
In elderly GC patients, the predominant well-differentiated
intestinal type adenocarcinoma generally tends to invade
Figure 1 Overall survival in gastric carcinoma according to age groups.
Figure 2 Disease free survival in gastric carcinoma according to age groups.
134 A.A. Zeeneldin et al.blood vessels and generate hematogenous metastases, predom-
inantly to the liver via the portal vein rather than the direct
peritoneum invasion [2,24,30]. This is conﬁrmed in the current
study wherein liver metastases were more frequently encoun-
tered than the peritoneal ones. However, due to small numbers
the difference in metastatic sites between elderly and non-
elderly patients was not statistically signiﬁcant.
Surgical resection accompanied by dissection of an
optimum number of lymph nodes is the only modality that is
potentially curative in GCs [31]. Earlier studies reported
20%-50% rates of curative resections in the elderly in the
1950’s–1980’s. This increased to 50%-75% in more recentstudies [2]. Kitamura et al. reported similar resection rates in
all three age groups studied: >80 years, 60–79 years and
40–59 years (88% vs. 94% vs. 98%, respectively) [32]. In the
current study, curative resections were similar in the elderly
and non-elderly (44.4% vs. 44.9%). The generally lower resec-
tion in the current study is related to the inclusion of more
patients with IV stage disease that are not candidates for cura-
tive resection. Contradicting with us, Hamzaki et al. reported
lower resections in the elderly than the non-elderly (52% vs.
75%) [28]. However, the cut-off age used was 60 years
and not 65 years as in the current study. Similar to Saidi
et al. we reported that the type of curative resection was not
Figure 3 Progression-free survival in gastric carcinoma according to age groups.
Gastric Carcinoma in Elderly Egyptians 135statistically different between the elderly and non-elderly [33].
However, the rates of total gastrectomy in the current study
surpassed the partial one and this is almost the reverse of the
Saidi et al. ﬁgures. Different patient population, tumor loca-
tion and extent within the stomach as well as the surgical
expertise could explain for this variance. Owing to the retro-
spective nature of the study, we could not adequately assess
the extent of lymphadenectomy (D1 vs. D2). Surgical risk as
determined by the American Society of Anesthesiologists
(ASA) score, is signiﬁcantly higher in the elderly patients
owing to higher comorbidities [2]. The correlation between
the ASA risk and postoperative mortality and morbidity in
elderly patients with GCs is in controversy [34,35]. In the cur-
rent study, comorbidities were expectedly higher in the elderly
patients than in the non-elderly ones. Similar to Orsenigo et al.
[35], we reported a similar 90-day mortality between the elderly
and non-elderly. This could be attributed to advances in surgi-
cal and anesthetic techniques coupled with improved perioper-
ative intensive care [2].
Despite R0 GC resections, a signiﬁcant percentage will
develop local–regional and/or distant recurrence [36]. Thus,
to improve survival after curative resection in high-risk
patients, adjuvant modalities are recommended [31]. Random-
ized controlled trials (RCTs) showed that DFS/RFS and OS
were improved with the use of adjuvant therapy [12,13,37].
The median DFS/RFS increased from 19 to 30 months with
CRT and from 13 to 19 months with ECF perioperative che-
motherapy. The 36-month DFS rate increased from 60% to
72% with S-1 chemotherapy. The median OS increased from
27 to 36 months with CRT and from 20 to 25 months with
ECF perioperative chemotherapy. The 36-month OS rate
increased from 70% to 80% with S-1 chemotherapy. The cur-
rent study showed the same trend both in the whole group as
well as in the younger ones. In the whole group, adjuvant ther-
apy signiﬁcantly improved DFS (23 vs. 5 months, p= 0.018)
and OS (35 vs. 11 months, p= 0.02) compared to no adjuvant
treatment. In the non-elderly, adjuvant therapy signiﬁcantlyimproved DFS (27 vs. 9 months, p= 0.006) and OS (36 vs.
11 months, p= 0.011) compared to no adjuvant treatment.
However in the current study, the surgery alone arm had lower
survival than the control arm in the mentioned trials. Reasons
for this might be different patient population, small sample
size and may be the poor prognostic features in the surgery
only group.
In GC key adjuvant RCTs, elderly patients only repre-
sented a fraction of the total study population [12,13,37]. Thus,
deﬁnitive clear conclusions are not reached regarding the use
of various modalities (perioperative chemotherapy, post-oper-
ative chemotherapy or post-operative chemo-radiotherapy) in
the elderly patients [2]. GC adjuvant RCTs did not ﬁnd notice-
able differences in beneﬁts or toxicities between elderly and
non-elderly patients [12,13,37]. This implies that elderly
patients receiving adjuvant therapy have better outcomes than
elderly patients in the surgery-alone arm and that elderly
patients derive comparable beneﬁts to those in the non-elderly.
Contrarily, elderly in the current study receiving adjuvant che-
motherapy drove no beneﬁts additional to those of curative
surgery and their outcomes were signiﬁcantly inferior to those
in the non-elderly.
Compared to no adjuvant treatment, we depicted that adju-
vant chemotherapy in the elderly patients did not signiﬁcantly
improve DFS (median of 3 vs. 4 months) or OS (median of 6
vs. 5 months). Despite the absolute numbers are very small
to substantiate this ﬁnding (adjuvant = 9, no adjuvant = 7),
a recent population-based retrospective study of >1000
patients showed that chemotherapy did not improve survival
in elderly patients. In fact, it tends to be detrimental [38].
Unfortunately, we also reported that elderly had signiﬁcantly
inferior DFS (median of 3 vs. 27 months) and OS (median of
6 vs. 36 months) compared to the non-elderly patients. While
this contradicts with RCTs [12,13,37], it is similar to a big
cohort of elderly GC patients [38] where advanced age at
diagnosis was associated with poor survival. In that study,
each year above 65 increases mortality by 3% [38]. The small
136 A.A. Zeeneldin et al.absolute numbers of the elderly patients who received adjuvant
therapy (n= 9) and the high proportion of deaths among
them (n= 6) contributed to the lower OS and DFS as death
is an event in both endpoints. Moreover, elderly patients in
the current study showed poor tolerance to adjuvant
chemotherapy as death following the ﬁrst cycle of adjuvant
chemotherapy was encountered in 67% of the elderly (4/6)
compared to 25% in the non-elderly patients (3/12). Addition-
ally, living patient received only one cycle of adjuvant
chemotherapy in 67% of the elderly (2/3) compared to 15%
of the non-elderly (4/26).
Palliative systemic chemotherapy offers survival advanta-
ges and better quality of life than best supportive care alone
and therefore represents the recommended treatment modal-
ity [31]. However, there is no single global standard regimen
for the treatment of advanced gastric cancer [31]. Moreover,
in elderly patients there is uncertainty regarding the extent of
systemic palliative chemotherapy that should be offered [2].
Several trials reported on the use of palliative various
chemotherapy regimens in the elderly patients [39–43]. These
trials reported response rates between 17%-53% and median
PFS/EFS between 3.1–6.4 months and median OS between
5–14 months and [39–43]. In the current study, response rate
in the elderly was 44.4% with a median PFS of 6 months
and median OS of 7 months. These represent the modest ﬁg-
ures that ﬁt within the range of the reported trials [39–43].
The higher ﬁgures in the mentioned trials may be related
to the use of more efﬁcacious regimens that incorporate
oxaliplatin, docetaxel and capecitabine. For example, oxalipl-
atin-containing regimens (FLFOX4, FLO, and FLOX)
produced 41%-53% RRs, 5.4–6.4 month PFS and
7.4–13.9 month OS in the elderly patients [15,40–42]. Similar
to Trumper et al. we reported that elderly and non-elderly
had comparable beneﬁts (RR, PFS and OS) and toxicities
[39].
The current study has strengths and limitations. Due to its
retrospective nature, it suffered some missing information and
we could not adequately address some important points. These
included information on risk factors (e.g. H. pylori, diet and
smoking, family history and Her-2 testing) and treatments
(e.g. the extent of lymphadenectomy and the use of trast-
uzumab). Nevertheless, and to the best of our knowledge, this
is the largest Egyptian study on gastric carcinoma that reports
on clinico-pathological features, treatments and outcomes.
In conclusion, GC in Egypt is not a common cancer among
the Egyptians. The median age is 54 years and 22.6% of the
cases are 65 years or more i.e. elderly. Apart from more prox-
imal locations and more differentiated histologies in the
elderly, clinical and pathological features were not signiﬁcantly
different in the elderly and non-elderly. Despite treatments
were largely comparable, univariate analysis showed that OS
and DFS were lower in the elderly compared to the non-
elderly. However, age was not an independent predictor of
poor OS, DFS or PFS in multivariate analysis. Thus, advanc-
ing age should not be the sole determinant of a treatment
modality. Nevertheless, treatments should be tailored to each
patient.
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